PURPOSE: @entity2686 ( @entity2686 ) 44 is a cell surface receptor that correlates with the development of drug resistance in @entity43 ( @entity43 ). Here, we prospectively investigated the clinical impact of @entity1759 expression on the development of chemoresistance, and on disease-free and overall survival in @entity43 . METHODS: This study included @entity1 with primary serous @entity43 that was at International Federation of Gynecology and Obstetrics stages IIIB-IVA and @entity5 that were @entity1759 positive and negative in a 1:1 ratio. All @entity1 underwent primary surgical cytoreduction, followed by six cycles of combined @entity1311 and @entity3003 chemotherapy every 3  weeks. The treatment was considered complete after the chemotherapy had finished. All @entity1 were followed up for 24  months after completing their chemotherapy. RESULTS: Of the 96 @entity1 with serous @entity43 at stages IIIB-IVA, 51  % of the @entity5 were negative for the expression of @entity1759 and 49  % showed variable @entity1759 expression. @entity1 who had @entity1759 -positive @entity5 had statistically significant shorter disease-free (p   <=  0.001) and overall survival (p   <=  0.001) intervals compared with @entity1 with @entity1759 -negative @entity5 . The hazard ratio for @entity204 was 6.8 (95  % confidence interval 2.4-19.2, p   <=  0.001) among the @entity1 with @entity1759 -positive @entity5 . A multivariate analysis showed that @entity3003 -resistant or @entity3003 -refractory @entity43 was the only independent predictive factor for @entity204 . CONCLUSIONS: @entity1759 expression contributes to the development of @entity3003 resistance in advanced serous @entity43 , and it may contribute to worse prognoses for @entity1 , but it is neither an independent predictor of survival nor of recurrence.

Clinical relevance of @entity1759 surface expression in advanced stage XXXX : a prospective study.

@entity43 :: ('MESH:D010051', 'Disease') :: ['EOC', 'epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2686 :: ('MESH:D003027', 'Disease') :: ['Cluster of differentiation', 'CD'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1759 :: ('960', 'Gene') :: ['CD44'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity43 :: (MESH:D010051,Disease) :: ['serous epithelial ovarian cancer']
